SCHEMBL13647859

SCHEMBL13647859

CN(Cc1ccccc1)c1cc(-n2cnc(Nc3ccccc3)n2)ccn1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CDC7 O00311 1/20 0.39
▸ ROCK2 O75116 1/20 0.39
▸ PIM1 P11309 1/20 0.39
▸ PRKACA P17612 1/20 0.39
▸ CDK2 P24941 1/20 0.39
▸ GSK3B P49841 1/20 0.39
▸ HIPK2 Q9H2X6 1/20 0.39
▸ IRAK4 Q9NWZ3 1/20 0.39
▸ MAP2K7 O14733 1/20 0.37
▸ BRD4 O60885 1/20 0.36
▸ CDK9 P50750 2/20 0.36
▸ CCNT1 O60563 1/20 0.36
▸ LOXL2 Q9Y4K0 1/20 0.36
▸ MAPK10 P53779 1/20 0.35
▸ MAPK13 O15264 1/20 0.35
▸ MAPK12 P53778 1/20 0.35
▸ MAPK11 Q15759 1/20 0.35
▸ MAPK14 Q16539 1/20 0.35
▸ CDK4 P11802 1/20 0.35
▸ KCNH2 Q12809 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13647862 0.93 LMNA (0.39) CDC7ROCK2PIM1PRKACACDK2
SCHEMBL14489538 0.86 TAAR1 (0.44) PIM1CDK2MAPK10MAPTKMT2A
SCHEMBL13647850 0.86 POLB (0.39) PIM1CDK2MAPK10MAPTTAAR1
SCHEMBL13513952 0.86 SYK (0.36) PIM1CDK2MAPK10CDK4MAPT
SCHEMBL13647855 0.85 TNK2 (0.36) CDK2MAPK10CDK4TAAR1JAK3
SCHEMBL2854241 0.84 SYK (0.37) CDK2MAPK10CDK4MAPTKMT2A
SCHEMBL2860934 0.84 GSK3B (0.38) GSK3BMAPK10CDK4LMNACYP1A2
SCHEMBL13513925 0.83 TSHR (0.37) CDK2CDK4TSHRKMT2AHTT
SCHEMBL13647857 0.78 CDK2 (0.37) PIM1CDK2MAPTTSHRLMNA
SCHEMBL13513926 0.78 RXFP1 (0.36) CDK2CDK4KDM4EJAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7598245-B2 Aminotriazole compounds useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-10-06 — — US disclosed
US-7598245-B2 Aminotriazole compounds useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-10-06 — — US disclosed
US-20080096901-A1 Aminotriazole compounds useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED 2008-04-24 — — US disclosed
US-20080096901-A1 Aminotriazole compounds useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED 2008-04-24 — — US disclosed
US-7226920-B2 Aminotriazole compounds useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INC. (US) 2007-06-05 — — US disclosed
US-7226920-B2 Aminotriazole compounds useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INC. (US) 2007-06-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080096901-A1 Aminotriazole compounds useful as inhibitors of protein kinases MAP3K20, MAP3K5, MAP3K1 CDC7 351/4885ROCK2 724/4885PIM1 214/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback